Silas Inman

Antibiotics followed by oral SER-109 demonstrated a low rate of recurrent clostridioides difficile infection through week 8, regardless of the number of prior episodes.

Extended induction treatment with upadacitinib 45 mg led to achievement of clinical response in a clinically meaningful proportion of patients with ulcerative colitis who do not respond to 8 weeks of induction therapy.

RBX2660 reduced clostridioides difficile infection recurrence at 8 weeks, with a sustained clinical response through 6 months, in an open-label phase 3 cohort of patients representative of real-world clinical practice.

Treatment with guselkumab resulted in greater improvements across key clinical and endoscopic/histologic outcome measures at week 12 compared with placebo in patients with moderately to severely active ulcerative colitis with or without a history of inadequate response or intolerance to advanced therapy.

Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.

Twelve additional weeks of subcutaneous risankizumab induction was efficacious and well-tolerated in patients with Crohn's disease following an initial risankizumab 12-week induction dose.

Risankizumab induction relieved Crohn's disease symptoms and maintenance doses were effective in resolving abdominal pain, with other mixed findings for other patient-reported outcomes in the maintenance phase.

Treatment with terlipressin led to better long-term clinical outcomes for patients with hepatorenal syndrome who received a liver transplant.

On-demand vonoprazan at all investigated doses was significantly better than placebo in providing rapid and sustained relief from heartburn episodes in patients with nonerosive reflux disease.

Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.

A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.

FDA grants emergency use authorization to a rapid point-of-care test to detect COVID-19 infection.

Results of a recent study from ASH 2019 is suggesting a combination of navitoclax and ruxolitinib could improve outcomes for patients with myelofibrosis.

Results of the phase 2 MANIFEST study presented at ASH 2019 suggest CPI-0610 could be an effective treatment for patients with refractory or intolerant advanced myelofibrosis.

The rAAV2/2-ND4 gene therapy GS010 elicited continuous bilateral improvements in BCVA from week 48 to week 96 for patients with Leber hereditary optic neuropathy.

Intraocular pressure at day 7 post MicroShunt implantation may be useful for predicting outcomes 1-year post procedure for patients with glaucoma.

A 0.002% concentration of sepetaprost demonstrated promising reductions in intraocular pressure (for patients with primary open-angle glaucoma or ocular hypertension.

Intravitreal aflibercept injection showed a high level of ≥2-step improvement in DRSS compared with sham for patients with moderately severe to severe nonproliferative diabetic retinopathy.

Treatment with subretinal transplantation of allogeneic human retinal progenitor cells showed promising early signs of efficacy as a treatment for individuals with retinitis pigmentosa.

AAV2/5-OPTIRPE65 showed improvements in vision-guided mobility, retinal sensitivity, and foveal-driven visual function for patients with RPE65-associated retinal dystrophy.

MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.

The FDA has approved the first-in-class CGRP monoclonal antibody erenumab for the prevention of migraines in adults, based on findings from three clinical trials.

Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.

The novel immune-based treatment IMCgp100 demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, advanced uveal melanoma.

Voretigene neparvovec demonstrated sustained improvements in vision for patients with biallelic RPE65-mutation–associated inherited retinal disease.

Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.

An automated artificial intelligence-based system was approximately 70% accurate at predicting optimal retreatment intervals for nAMD.

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.